News + Font Resize -

PharmaCell signs pact for contract manufacturing with Dendreon' Provenge in Europe
Maastricht, The Netherlands | Friday, October 25, 2013, 16:00 Hrs  [IST]

PharmaCell, a leading European-based CMO, has entered into an agreement with Dendreon Corporation to be the Contract Manufacturing Organisation (CMO) for the European commercial production of its recently approved cellular immunotherapy product Provenge (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) dispersion for infusion.

In September, the European Commission (EC) granted marketing authorization for Provenge in the European Union for the treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) castrate resistant prostate cancer in male adults in whom chemotherapy is not yet clinically indicated. In the United States, Provenge was approved in 2010 and is produced by Dendreon in its own manufacturing facilities.

Alexander Vos, chief executive officer of PharmaCell BV said, “We are extremely pleased that an immunotherapy industry leader such as Dendreon has decided to continue its relationship with PharmaCell. We have worked with Dendreon since 2011, and the decision to extend our relationship is a testament to the dedication and expertise of our team who have worked with Dendreon throughout the Technology Transfer and European approval process over the past few years.”

PharmaCell is a leading European-based CMO active in the area of cell therapy and regenerative medicine. The company is exclusively focused on providing contract services in the area of human cell therapy.

Post Your Comment

 

Enquiry Form